Randomised trial comparing the effectiveness of ticagrelor and prasugrel in patients with ST segment elevation myocardial infarction (STEMI) who have been treated with primary PCI.
start of the project: 10/2013
The randomised multicentre trial Prague 18 involves patients with acute myocardial infarction who have been indicated for primary percutaneous coronary intervention (PCI). Patients are subsequently randomised into one of the following treatment arms. Arm 1: Patients receive prasugrel at a loading dose of 60 mg and a maintenance dose of 10(5) mg/day. Arm 2: Patients receive ticagrelor at a loading dose of 180 mg and a maintenance dose of twice 90 mg/day.
- Expert guarantor: Assoc. Prof. Zuzana Motovska, M.D., Ph.D. (Czech Society of Cardiology)
- Partners: 11 cardiology centres in the Czech Republic
- Brief overview of results: Motovska Z, Hlinomaz O, Kala P, et al. One-year outcomes of prasugrel versus ticagrelor in acute myocardial infarction treated with primary angioplasty: the PRAGUE-18 study. Journal of the American College of Cardiology 2017. doi: 10.1016/j.jacc.2017.11.008
- Anaesthesiology, intensive care medicine
- Cardiology, angiology
- Diabetology, dietetics
- Educational projects
- Emergency medicine, toxicology
- Endocrinology, metabolism
- Gastroenterology, hepatology
- Haematology, haematological oncology
- Immunology, allergology
- Medical genetics
- Nephrology
- Neurology, neurosurgery
- Nursing care
- Obstetrics, gynaecology
- Oncology, radiotherapy
- Ophthalmology
- Paediatrics, neonatology
- Pathology, laboratory medicine
- Pulmonary medicine
- Rheumatology, physiotherapy
- Screening programmes
- Surgery, traumatology, orthopaedics
- Urology